miR-21 is often described as an oncomiR due to its role in promoting tumorigenesis. In pediatric cancers, such as neuroblastoma and rhabdomyosarcoma, miR-21 has been found to be overexpressed. This overexpression can lead to the inhibition of tumor suppressor genes, thereby promoting cell proliferation and survival, and contributing to cancer progression. Targeting miR-21 could therefore be a potential therapeutic approach in treating pediatric cancers.
